Neuland Laboratories Ltd
Neuland Laboratories Ltd (NEULANDLAB) last reported results for the quarter ended Jun 2026, with sales of ₹642 crore and net profit of ₹148 crore. The stock last traded at ₹21,522, a market capitalisation of ₹27,612 crore, on a P/E of 55.5. Over the past 52 weeks the stock has ranged between ₹11,500 and ₹24,235. Figures are as of 6 Oct 2026 and are not real time.
Neuland Laboratories Ltd share price and key metrics
- Current price
- ₹21,522
- Market cap
- ₹27,612 cr
- Stock P/E
- 55.5
- Book value
- ₹1,461
- ROE
- 21.2%
- ROCE
- 26.5%
- Dividend yield
- 0.16%
- 52w high / low
- 24235/11500
Metrics as of 6 Oct 2026. Not real time.
Track Neuland Laboratories Ltd
Cruxal reads every Neuland Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Neuland Laboratories Ltd growth and returns
- 10 Years
- 15%
- 5 Years
- 17%
- 3 Years
- 19%
- TTM
- 78%
- 10 Years
- 29%
- 5 Years
- 39%
- 3 Years
- 30%
- TTM
- 278%
- 10 Years
- 36%
- 5 Years
- 71%
- 3 Years
- 77%
- 1 Year
- 44%
- 10 Years
- 14%
- 5 Years
- 18%
- 3 Years
- 20%
- Last Year
- 21%
Neuland Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹642 cr, up 119.1% from ₹293 cr a year earlier. Net profit was ₹148 cr, up 957.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 311 | 398 | 328 | 293 | 514 | 440 | 776 | 642 |
| Expenses | 249 | 311 | 277 | 258 | 359 | 363 | 469 | 419 |
| Operating profit | 62 | 87 | 51 | 34 | 156 | 77 | 307 | 223 |
| OPM % | 20% | 22% | 16% | 12% | 30% | 18% | 40% | 35% |
| Other income | 4 | 60 | 7 | 8 | 2 | 8 | 12 | 8 |
| Interest | 1 | 2 | 2 | 5 | 5 | 7 | 7 | 7 |
| Depreciation | 16 | 16 | 17 | 20 | 23 | 24 | 25 | 27 |
| Profit before tax | 49 | 128 | 39 | 18 | 129 | 54 | 287 | 198 |
| Tax % | 34% | 20% | 29% | 21% | 25% | 26% | 26% | 25% |
| Net profit | 33 | 102 | 28 | 14 | 97 | 41 | 213 | 148 |
| EPS (₹) | 25.60 | 79.18 | 21.68 | 10.83 | 75.49 | 31.62 | 165.76 | 115.10 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Neuland Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 579 | 527 | 667 | 763 | 937 | 951 | 1,191 | 1,559 | 1,477 | 2,023 | 2,372 |
| Operating profit | 106 | 51 | 58 | 102 | 147 | 144 | 273 | 463 | 331 | 580 | 763 |
| OPM % | 18% | 10% | 9% | 13% | 16% | 15% | 23% | 30% | 22% | 29% | 32% |
| Net profit | 47 | 12 | 16 | 16 | 81 | 64 | 164 | 300 | 260 | 364 | 498 |
| EPS (₹) | 52.74 | 13.57 | 12.81 | 12.63 | 62.85 | 49.74 | 127.45 | 233.89 | 202.74 | 283.71 | 387.97 |
TTM is the trailing twelve months to the most recent quarter.
Neuland Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 9 | 9 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 537 | 549 | 686 | 697 | 774 | 828 | 981 | 1,270 | 1,512 | 1,862 |
| Borrowings | 192 | 319 | 231 | 264 | 182 | 241 | 128 | 95 | 157 | 301 |
| Other liabilities | 148 | 194 | 200 | 257 | 356 | 302 | 457 | 454 | 498 | 754 |
| Total liabilities | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,833 | 2,180 | 2,930 |
| Fixed assets | 466 | 475 | 542 | 653 | 716 | 767 | 758 | 824 | 955 | 1,177 |
| CWIP | 20 | 126 | 104 | 24 | 17 | 20 | 41 | 46 | 48 | 211 |
| Investments | 8 | 8 | 8 | 8 | 7 | 4 | 1 | 1 | 109 | 2 |
| Other assets | 393 | 463 | 476 | 547 | 585 | 592 | 781 | 962 | 1,068 | 1,541 |
| Total assets | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,833 | 2,180 | 2,930 |
As reported by the company. Total assets equal total liabilities by construction.
Neuland Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 39 | 11 | 70 | 57 | 189 | 60 | 237 | 261 | 317 | 347 |
| Cash from investing | -42 | -116 | -77 | -49 | -84 | -95 | -61 | -150 | -298 | -423 |
| Cash from financing | -0 | 105 | 12 | -5 | -114 | 38 | -136 | -69 | 25 | 21 |
| Net cash flow | -4 | -0 | 5 | 3 | -9 | 3 | 40 | 42 | 44 | -55 |
| Free cash flow | -2 | -121 | 7 | 9 | 84 | -37 | 173 | 119 | 112 | -50 |
| CFO / operating profit | 52% | 28% | 128% | 61% | 132% | 56% | 103% | 81% | 119% | 78% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Neuland Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 16% | 4% | 4% | 8% | 11% | 10% | 21% | 33% | 19% | 26% |
| Debtor days | 114 | 134 | 90 | 91 | 85 | 90 | 111 | 87 | 78 | 98 |
| Inventory days | 186 | 266 | 191 | 209 | 205 | 227 | 211 | 220 | 238 | 245 |
| Days payable | 118 | 189 | 118 | 110 | 126 | 100 | 129 | 121 | 156 | 129 |
| Cash conversion cycle | 182 | 211 | 162 | 190 | 164 | 216 | 193 | 187 | 160 | 214 |
| Working capital days | 44 | 38 | 138 | 137 | 60 | 74 | 81 | 88 | 76 | 75 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Neuland Laboratories Ltd shareholding pattern
Promoters held 32.62% at Jun 2026, broadly unchanged since Jun 2025. FIIs 21.08% and DIIs 16.52%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 32.64% | 32.68% | 32.67% | 32.67% | 32.64% | 32.63% | 32.63% | 32.62% |
| FIIs | 26.46% | 23.86% | 22.12% | 21.69% | 20.60% | 20.90% | 20.46% | 21.08% |
| DIIs | 6.38% | 9.09% | 10.97% | 11.57% | 13.55% | 14.72% | 15.84% | 16.52% |
| Government | 0.40% | 0.40% | 0.40% | 0.40% | 0.40% | 0.00% | 0.00% | 0.00% |
| Public | 34.12% | 33.96% | 33.85% | 33.67% | 32.80% | 31.76% | 31.08% | 29.79% |
| No. of shareholders | 34,567 | 39,315 | 39,333 | 42,419 | 44,393 | 46,187 | 46,304 | 44,340 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Neuland Laboratories Ltd corporate filings
- Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018Company Updatelow impact
- Closure of Trading WindowInsider Trading / SASTlow impact
- Neuland Laboratories schedules analyst and institutional investor meetings for September 23-25, 2026Company Updatelow impact
Cruxal's analysis: Neuland Laboratories has announced a schedule for meetings with analysts and…
Read the full analysis - Neuland Laboratories Ltd releases routine press release under Regulation 30Company Updatelow impact
Cruxal's analysis: Neuland Laboratories has filed a press release under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Neuland Laboratories schedules analyst and institutional investor meetings for September 15 and 17, 2026Company Updatelow impact
Cruxal's analysis: Neuland Laboratories has announced a schedule for analyst and institutional investor…
Read the full analysis - Neuland Laboratories Ltd: Disclosure under Regulation 30 of SEBI Listing RegulationsCompany Updatelow impact
Cruxal's analysis: Neuland Laboratories has filed a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Neuland Laboratories Limited receives credit rating reaffirmation from CRISIL with an outlook upgrade to 'Positive'Company Updatemedium impact
Cruxal's analysis: Neuland Laboratories Limited has announced that CRISIL Ratings has reaffirmed its…
Read the full analysis - Neuland Laboratories Ltd: Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: Neuland Laboratories Ltd has published its financial results in newspapers as per…
Read the full analysis - Malabar India Fund Limited reduces stake in Neuland Laboratories Limited by 2.12% via open market saleInsider Trading / SASTmedium impact
Cruxal's analysis: Malabar India Fund Limited has disclosed a reduction in its shareholding in Neuland…
Read the full analysis - Neuland Laboratories confirms completion of US FDA inspectionCompany Updatelow impact
Cruxal's analysis: Neuland Laboratories has formally intimated the completion of a US FDA inspection at its…
Read the full analysis - Neuland Laboratories Reports Strong Q1 FY27 Financials with 16.3% Revenue Growth and Strategic Gland Pharma CollaborationCompany Updatehigh impact
Cruxal's analysis: Neuland Laboratories Limited reported Q1 FY27 total income of 650.1 crore, up 16.3% YoY…
Read the full analysis - Neuland Laboratories Ltd schedules analyst/institutional investor meeting for August 12, 2026Company Updatelow impact
Cruxal's analysis: Neuland Laboratories has announced a scheduled meeting with analysts and institutional…
Read the full analysis - Neuland Laboratories Ltd: Publication of Newspaper Notice regarding Regulation 30Company Updatelow impact
Cruxal's analysis: Neuland Laboratories Ltd has published a notice in newspapers in compliance with…
Read the full analysis - Neuland Laboratories announces manufacturing capacity enhancementCompany Updatemedium impact
Cruxal's analysis: Neuland Laboratories has disclosed an enhancement of its manufacturing capacity under…
Read the full analysis - Neuland Laboratories executes deed of corporate guaranteeCompany Updatelow impact
Cruxal's analysis: Neuland Laboratories has executed a deed of corporate guarantee in compliance with…
Read the full analysis - Neuland Laboratories Reports Strong Q1 FY27 Financials with 116.3% YoY Revenue Growth and 975% PAT SurgeCompany Updatehigh impact
Cruxal's analysis: Neuland Laboratories Limited delivered robust Q1 FY27 results, reporting a total income…
Read the full analysis - Neuland Laboratories Reports Strong Q1 FY27 Results with 116.3% YoY Revenue Growth and 975% PAT SurgeCompany Updatehigh impact
Cruxal's analysis: Neuland Laboratories Limited delivered robust Q1 FY27 financial results, reporting total…
Read the full analysis - Neuland Laboratories Reports Strong Q1 FY27 Results and Announces Strategic Sterile API Partnership with Gland PharmaResulthigh impact
Cruxal's analysis: Neuland Laboratories Limited reported robust Q1 FY27 consolidated revenue of 641.58 crore…
Read the full analysis - Neuland Laboratories Adopts Strong FY26 Financials, Declares INR 34 Dividend Amidst Massive Q4 EPS BeatAGM/EGMhigh impact
Cruxal's analysis: Neuland Laboratories Limited's 42nd Annual General Meeting held on August 4, 2026…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.